glucagon is the most under-discussed thing in c/scamalerts
Something I noticed reading old threads that I have not seen said out loud. The advice on hepatic fat in this community changed substantially around the start of last year, and nobody went back and updated the older posts. So depending on which thread the search engine hands you, you get two contradictory answers…
the MASH indication changes the risk calculus
The confident tone is doing a lot of work that the evidence is not.
Sceptical. If this were true we would see it reflected in the data and we do not.
MASH claims need the trial and the biopsy endpoint
the GLP-1/glucagon dual is hepatic fat, different from GIP/GLP-1
do not generalise from tirzepatide